Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

• Status: Not yet recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Gabapentin

Criteria

Inclusion Criteria:

• Men and women between the ages of 18 and 65 years

• Residing within the states of Missouri or Illinois

• Clinically diagnosed or subjective olfactory dysfunction (anosmia, hyposmia, or parosmia) of 3 months duration or longer diagnosed within 2 weeks of Covid-19 infection

• UPSIT score consistent with diminished olfactory function (score ≤ 33 in men and ≤ 34 in women).

• Willing to respond daily to study surveys, preferably through smartphone with unlimited texting plan

• In possession of ALL 7 household items: soap, burnt candle, peanut butter, herb, garlic, lemon, and coffee

Exclusion Criteria:

• Clinically diagnosed olfactory dysfunction secondary to genetic abnormalities or congenital dysfunction, trauma, non-Covid-19 viral infection, nasal polyps, neurodegenerative disorders

• Current use of: azelastine, bromperidol, orophenadrine, oxomemazine, kratom, paraldehyde, or thalidomide

• History of addiction to alcohol, cocaine, or opioids

• Impaired renal function, myasthenia gravis, or myoclonus

• Severe allergy to peanuts

• Pregnancy or attempting pregnancy during study participation

• Inability to participate in virtual trial due to lack of access to the internet or unlimited text messaging; inability to comprehend or use English language

• Availability less than 6 months from time of enrollment

• Residency in states other than Missouri or Illinois.